Short-Term Debt to Equity Ratio: Firefly Neuroscience, Inc (AIFF)
Firefly Neuroscience, Inc (AIFF) is implementing an advanced cloud-based system for digital EEG decoding, creating visual brain activity maps to detect depression and Alzheimer's disease. Financial stability is currently limited by the development stage of AI services, but revenue is expected to grow as the company scales across clinics. The price indicator on the chart, where the metric reaches 0.00, illustrates the company's struggle for the neurodiagnostics market against traditional methods.
fireflyneuro.com - analytical breakdowns and key metrics (AIFF)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Firefly Neuroscience, Inc|AIFF - Long-Term Liabilities to Equity|Short-Term Debt to Capital Firefly Neuroscience|AIFF - Company Total Debt Obligations|Debt to Book Capitalization Ratio Firefly Neuroscience Inc|AIFF - Company Long-Term Loans and Borrowings|Company Short-Term Debts Firefly Neuroscience|Quick Ratio fireflyneuro.com
- company profitability and valuation multiples indicators:
Basic company analysis:AIFF Firefly Neuroscience Inc
This indicator determines the extent of the company's dependence on obligations maturing within one year relative to its equity, allowing for an assessment of liquidity risk. By analyzing the change in the ratio of short-term debt to equity, an investor can observe the balance between financial stability and leverage, which is critical for Firefly Neuroscience, Inc (AIFF) during the scaling phase of its AI platform following FDA approval amid currently limited sales volumes.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|denalitherapeutics.com - Current Liabilities to Equity|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Coefficient Biohaven Ltd|Short-Term Debt to Equity Amylyx AMLX|Ratio of Short-Term Indebtedness to Capital TRVI|Praxis Precision Medicines - Short-Term Debt to Capital|Current Liabilities to Capital anavex.com|CBLL: Short-Term Debt to Capital|Current Liabilities to Equity PRTA (Prothena Biosciences)|Short-Term Debt to Equity Alector Inc.|Short-Term Debt to Equity ANNX|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|NGNE - Current Liabilities to Capital|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA - Short-Term Debt to Equity|SCLX (Scilex Holding Company, Inc.) - Short-Term Debt to Capital Ratio|TVGN: Short-Term Debt to Capital|Current Liabilities to Capital Alpha Cognition Inc. (ACOG)|Short-Term Debt to Equity Ratio CGTX|Short-Term Debt to Capital Inhibikase Therapeutics Inc|Short-Term Debt to Equity Cassava (SAVA)|ASRT (assertiotx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Current Liabilities to Capital|OVID - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Acumen Pharmaceuticals Inc. ABOS|CRVO: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Alterity Therapeutics Limited|CLNN (Clene Inc) - Short-Term Debt to Capital|PepGen Corp (PEPG) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital JUNS|RLMD - Current Liabilities to Capital|Short-Term Debt to Equity Annovis Bio Corp ANVS|GRCE: Short-Term Debt to Capital Ratio|ANEW Medical, Inc. - Short-Term Debt to Capital|NeuroSense Therapeutics (NRSN) - Short-Term Debt to Equity Ratio|RVPH: Short-Term Debt to Capital|Current Liabilities to Capital MetaVia (MTVA)|Short-Term Debt to Equity Ratio NRXS|HSDT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital PASG|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|ATHA: Short-Term Debt to Capital Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Alzamend Neuro, Inc. (ALZN) - Short-Term Debt to Equity Ratio|CYCN: Short-Term Debt to Capital|Protagenic Therapeutics, Inc. (PTIX) - Short-Term Debt to Capital|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Cortigent Medical (CRGT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital ATXI|BCLI: Current Liabilities to Equity|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|CHRO (chromocell.com) - Current Liabilities to Equity|ELYM - Short-Term Debt to Equity|ITCI (Intra-Cellular Therapies) - Short-Term Debt to Capital Ratio|LBPH: Short-Term Debt to Capital|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity Ratio NKGN|Short-Term Debt to Capital neurobopharma.com|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX (Synaptogenix Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|Anew Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Equity CERE